Related Experiment Videos
Bleeding time is prolonged during oral anticoagulant therapy.
F Marongiu1, G Biondi, G G Sorano
1Istituto di Medicina Interna, Università di Cagliari, Italy.
Thrombosis Research
|September 15, 1990
Summary
Oral anticoagulant therapy can prolong bleeding time (BT), especially during overdose. A linear correlation exists between BT and Thrombotest (TT), suggesting primary hemostasis issues in patients on anticoagulation.
Area of Science:
- Hematology
- Clinical Pathology
Background:
- Oral anticoagulant therapy (OAT) requires careful monitoring to prevent bleeding complications.
- Thrombotest (TT) is a common method for monitoring OAT, but its correlation with bleeding time (BT) requires further investigation.
Purpose of the Study:
- To investigate the relationship between bleeding time (BT) and Thrombotest (TT) in patients undergoing oral anticoagulant therapy.
- To assess the impact of anticoagulation status (steady state vs. overdose) on BT.
Main Methods:
- Bleeding time (BT) was measured in 55 patients on OAT monitored by Thrombotest (TT).
- Patients were categorized into steady state anticoagulation and overdose phases.
- BT values were compared to normal controls and analyzed for correlation with TT.
Main Results:
- Patients in steady state anticoagulation exhibited longer BT than controls.
- Patients in the overdose phase showed significantly longer BT compared to controls and those in steady state.
- A significant linear correlation was observed between BT and TT values.
- BT values normalized after recovery from the overdose phase.
Conclusions:
- Bleeding time is prolonged in patients on oral anticoagulant therapy, particularly during overdose.
- A significant linear correlation between BT and TT suggests that TT monitoring may reflect bleeding risk.
- Primary hemostasis impairment may involve fibrin deposition or a vitamin K-dependent vascular factor.